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Introduction
Seasonal allergic rhinitis (SAR), commonly known as hayfever, is a 
common and growing challenge in Primary Care. Increasing numbers 
of patients present with symptoms [1] and suboptimal use of medi-
cation is widespread [2]. The reported incidence of SAR is between 
2-15%, depending on the diagnostic criteria and population [3]. The 
prevalence of SAR in UK school children has increased since the 1960s 
[1,4,5] and the lifetime prevalence of SAR also continues to increase 
in adults [6]. This rising prevalence has been reflected in increased use 
of health services. Consultations with general practitioners (GPs) have 
increased [1]: the number of patients of all ages consulting GPs for SAR 
in England and Wales (ICD9-477) doubled between 1971-1991 [6]. 
Between 1991 and 2004, Primary Care prescriptions for nasal allergy 
increased by over 60% (from 2.7 to 4.5 million/year) and ocular anti-
inflammatory prescriptions increased by 50% to 1.4 million/year [6]. 
While increases in prevalence statistics may reflect increased patient 
awareness or altered diagnostic practice, the increase in prescriptions 
does confirm that more people are seeking treatment for SAR [7]. 
Common symptoms of SAR include sneezing, runny or blocked 
nose and itchy eyes [2,8]. Despite the availability of a wide range of 
symptom-relieving medications, SAR can significantly affect suffer-
ers’ perceived health and quality of life [9-14]. Only a minority of SAR 
patients report good symptom control, although this statistic may be 
skewed because many people with SAR (44%) do not consult a clinician 
[15]. Suboptimal use of medication and poor symptom control may 
result from not taking medications as instructed [2], which in other 
illnesses has been shown to be influenced by patients’ beliefs [16,17].
Leventhal’s Common Sense Model of self regulation of health and 
illness (SRM), provides a three-stage framework for understanding 
how symptom-based and psychological factors combine to form pa-
tients’ own model of illness and how this influences coping strategies 
and outcomes [18,19]. Firstly, the person constructs cognitive and emo-
tional representations of the health threat. These reflect internal cues 
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Abstract
Background: Although effective medication for hayfever (seasonal allergic rhinitis) is available, treatment 
outcomes are often be poor. Patient beliefs influence outcomes in many other diseases. Assessing patients’ beliefs 
about their illness and medication may identify targets for intervention to optimize self management and lessen 
disease impact. 
Objective: The application of validated health-related analytical models (Leventhal’s illness representations and 
Horne’s beliefs about medications) to explore patients’ understanding and experience of hayfever and its treatment. 
Methods: Cross-sectional postal questionnaire sent to 20% sample of adults attending four General Practices in 
South England and prescribed medication for hayfever symptoms in the previous two years. Measures included the 
Revised Illness Perception Questionnaire and the Beliefs about Medicines Questionnaire. 
Results: 316/586 questionnaires were returned (54%). Cluster analysis identified two patient groups; those with 
negative beliefs (n=132) and those with more positive beliefs about hayfever and its treatment (n=182). Those with 
negative beliefs were more likely to believe that their hayfever would last for a long time, that they have little personal 
control over their illness and that their treatment is not effective. Conversely, they reported greater consequences, 
greater emotional impact, less understanding of hayfever and more medication concerns than those with more 
positive beliefs. 
Conclusions and clinical relevance: Patients with hayfever fall into two distinct groups: nearly half (41% of 
those sampled) have negative beliefs about their condition. Eliciting patient beliefs during the consultation may 
reveal assumptions that differ from those of healthcare professionals. Such beliefs should be considered when 
negotiating treatment plans.
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(symptoms), and/or external cues (information from friends, family 
and healthcare professionals). Five cognitive representations are de-
scribed: identity: the signs and symptoms and the arbitrary label given 
to the condition; cause: the individual’s perceived cause of the condi-
tion, which may differ from healthcare professionals’ views; time-line: 
beliefs about the likely duration of the condition; consequences: beliefs 
about the consequences of the condition for the individual and his/her 
life; curability/controllability: beliefs about whether the condition can 
be cured or controlled, including how much the individual can con-
trol this. Alongside these cognitive representations, the SRM includes 
emotional representations which reflect the emotional responses to the 
condition. 
At stage two, the individual adopts an action plan or coping pro-
cedure linked to their beliefs and emotions. Personal strategies may 
aim to achieve and maintain symptomatic control by seeking advice 
and medication (problem-focused coping) or may involve avoiding go-
ing outdoors, taking time off work, or reducing anxiety by meditating 
(emotion-focused coping). The third stage is coping appraisal, which 
involves evaluating the effectiveness of the coping strategy in dealing 
with the threat (in this case the symptoms of SAR). This evaluation 
feeds back to influence illness representations and coping strategies. 
The underlying aim is to restore the status quo, cognitively, physically 
and emotionally. If the patient is prescribed medication, their beliefs 
about medication will probably impact on coping mechanisms and out-
comes [20] so it is useful to measure these in addition to illness beliefs 
[16,21]. 
The SRM has been used to study patient beliefs in many illnesses 
[22-24] including asthma [16,25,26], leading to better understanding of 
how patients perceive and cope with chronic conditions and how beliefs 
affect health outcomes such as depression and quality of life. In patients 
with myocardial infarction (MI) interventions to change inappropriate 
cognitions regarding their illness have facilitated faster recovery rates 
[27] and provided patients with a greater sense of control over their 
illness [28]. Research on self-managed illnesses such as asthma has ad-
dressed the impact of illness and medication beliefs on adherence to 
medication [16,25,26] but these findings still await translation into ef-
fective patient interventions.
The illness representations of patients with SAR have not been stud-
ied, although one recent study looked at allergies in general [29]. The 
present study aimed to explore the beliefs that SAR patients hold re-
garding their illness and treatments, and to determine whether patients 
could be usefully classified according to the configuration of their ill-
ness beliefs. 
Methods
Design
Cross-sectional postal questionnaire survey.
Participants
Adult patients (aged 17-65 years) who had consulted with SAR at 
least once in the preceding two years were identified from computer-
ised records of four General Practices in Southern England.
Procedure
Questionnaires were distributed to a 20% random sample of pa-
tients with SAR in August, at the end of the grass pollen season. Self-
completion packs were distributed with a covering letter from the GP, 
and a freepost reply envelope. 
Demographic and descriptive data
Age, gender, current symptoms and age of symptom onset were col-
lected by questionnaire. 
Measures
The following self-completed measures were used to elicit illness 
representations and medication beliefs: 
Revised Illness Perception Questionnaire (IPQ-R): The revised 
Illness Perception Questionnaire (IPQ-R) [30] was chosen to assess pa-
tient’s beliefs and understanding of their illness, as it has proven validity 
and reliability across a range of illness groups. It provides a quantitative 
measure of the nature and strength of patient cognitions and emotional 
representations on nine subscales. 
The illness identity scale assesses the number and nature of symp-
toms that patients endorse as part of their condition. Participants are 
asked to state whether they have experienced any of 14 general symp-
toms (e.g. fatigue, sore eyes, headaches, sleep difficulties) since their 
illness began. They are then asked whether they believe the symptom 
to be specifically due to hayfever (yes/no) which are then summed to 
give the illness identity subscale score. The causal scale assesses personal 
perceptions of the likely cause of the illness and contains a core set of 18 
belief items (e.g. pollution, diet, overwork). For this study ‘pollen’ was 
added as an additional causal item. 
Illness cognitions are assessed through five subscales: perceived 
consequences of the illness (6 items, score 6-30) concerned with the 
expected effects and outcomes of the illness e.g. ‘my hayfever causes 
difficulties for those that are close to me’; how much personal control 
the patient feels they have over their illness (6 items, score 6-30) e.g. 
‘what I do can determine whether my hayfever gets better or worse’; 
timeline-chronic assesses how long the patient thinks their illness will 
last (6 items, score 6-30) e.g. ‘I expect to have hayfever for the rest of 
my life’; timeline -cyclical assesses perceptions about the pattern of their 
symptoms (4 items, score 4-20) e.g. ‘my symptoms come and go in cy-
cles’; and treatment control assesses the impact of treatment on control 
of the condition (5 items, score 5-25) e.g. ‘my treatment can control my 
hayfever’. The emotional representation the patient holds towards their 
illness (6 items, score 6-30) e.g. ‘I get depressed when I think about my 
hayfever’ and illness coherence/understanding which assesses whether 
patients’ comprehend their illness (5 items, score 5-25) e.g. ‘I have a 
clear picture or understanding of my hayfever’ are also assessed. These 
seven subscales are computed from responses to a series of statements 
to which the respondent indicates their agreement on a 5-point Likert 
scale, ranging from 1=strongly disagree to 5=strongly agree. Higher 
scores indicate stronger beliefs. 
 Beliefs about Medicines Questionnaire-Specific (BMQ-specific): 
Patients’ views about the medication prescribed for their hayfever were 
assessed using the Specific version of the Beliefs about Medicines Ques-
tionnaire (BMQ), which has been validated for use in a range of clinical 
conditions and has been shown to have good internal consistency and 
test-retest reliability [31]. The BMQ-specific measure comprises two 
5-item scales assessing personal beliefs about the necessity of the spe-
cifically prescribed medication for controlling their illness and concerns 
about the potential adverse consequences of taking it. In the BMQ-HF 
devised for this study, the word ‘medicines’ was replaced with ‘antihis-
tamine tablets’, ‘nasal spray’ and ‘eye drops’, to create three versions of 
the specific measure. Respondents indicate their degree of agreement 
with each of the 10 items on a 5-point Likert scale, (1=strongly disagree; 
5=strongly agree). Items are summed to give a necessity and concerns 
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scale scores (each ranging from 5-25). Higher scores indicate stronger 
beliefs in necessity and greater concerns about the particular medica-
tion. 
Statistical analysis
Statistical analysis was conducted using SPSS v14 for Windows. 
Missing items from IPQ-R scales were addressed by mean imputation 
as advised by the scale developer: if more than half of the subscale items 
were completed, the missing items were assigned values equal to the 
average of the completed items. 
Results
Participants
Of the 586 questionnaires sent, 316 were returned (54% response 
rate). 61% of respondents were female (61%); mean age 40 years (SD 
12.47). 81% reported moderate or severe symptoms and 76% reported 
symptoms ≥ 4 days/week for more than 4 weeks in the preceding hayfe-
ver season. 63% reported using oral antihistamines regularly, 37% used 
nasal sprays regularly and 22% used eye drops regularly (Table 1). 
Patient beliefs
All illness and treatment belief subscales demonstrated acceptable 
internal consistency with Cronbach’s Alpha ranging from 0.70-0.91 
(Table 2). 
The most common symptoms attributed to SAR were sore eyes 
(91%), sore throat (66%), wheeziness (63%), fatigue (55%), breathless-
ness (55%), sleep difficulties (53%) and headaches (49%). Some partici-
pants blamed hay fever for symptoms not commonly associated with 
SAR, e.g. upset stomach, loss of strength, pain, and nausea.
As causes of SAR, patients mainly endorsed immune and risk fac-
tors beyond their control, such as pollen (93%), pollution (73%), in-
herited condition (43%), altered immunity (32%). Fewer respondents 
selected psychological attributions such as stress/worry (16%), or emo-
tional state (9%) (Table 3) [30].
Relationships between patient beliefs and demographic fac-
tors
Females were more likely than males to believe that their hayfever 
was permanent or would last a long time (p=0.025). With increasing 
age, perceptions of personal controllability of their illness increased 
(r=0.13; p=0.025) as did beliefs about needing to take antihistamines 
(r=0.15; p=0.015) and concerns about nasal sprays (r=0.19; p=0.009). 
Later onset of SAR correlated positively with stronger perceptions 
of controllability of illness by treatment (r=0.14; n=297; p=0.019), 
more concerns about antihistamines (r=0.17; p=0.01) and nasal sprays 
(r=0.15; p=0.047), and weaker beliefs that hayfever would last a long 
time or be permanent (r=-0.15; p=0.008). 
People with earlier age of onset were more likely to report better 
understanding of their hayfever (illness coherence) than those whose 
symptoms started later (r=-0.28; n=297; p ≤ 0.001). Longer illness dura-
tion was associated with stronger beliefs in personal control (r=0.25; 
p ≤ 0.001), weaker beliefs in treatment control (r=-0.12; p=0.03), per-
ceptions that the illness would continue (r=0.15; p=0.008) and a bet-
ter understanding of the illness (illness coherence) (r=0.30; p ≤ 0.001). 
Although statistically significant, these relationships were all relatively 
modest.
Relationships between illness and medication beliefs (Table 
4)
Moderate associations (r ≥ 0.4) were found between beliefs that SAR 
has more severe consequences for the individual and concerns about 
medication. Stronger beliefs in the necessity for antihistamines were 
related to stronger illness identity and to more negative perceptions of 
the consequences of SAR. Participants reporting a better understand-
ing of their illness (high illness coherence scores) tended to have fewer 
concerns about medication (nasal spray, antihistamine tablets and eye 
drops) than those reporting poor understanding of their SAR (Table 4). 
Demographic variable N   (%)
Male
Female
121    
194 
(38)
(62)
Current age (years) :
  Mean (SD)
40.3 (12.47)
  Median 40
  Range 17-65
Experience of hay fever
Age developed hay fever (years): 
 Mean (SD) 
19.39 (12.62)
  Median 16
Duration of symptoms (years):
  Mean (SD)
  Median 21 20 (12.70)
Self-reported severity of symptoms: N (%)
  Mild 
  Moderate 
  Severe
63   
192   
50 
(21)
(63)
(16)
Experiencing symptoms ≥ 4 days per 
week for more than 4 weeks 201  (76)
Medication use
Oral antihistamines: Regular 198 (65)
 Occasional 78  (26)
Never 27 (9)
Nasal spray: Regular 116 (39)
Occasional 98  (33)
Never 84  (28)
Eye drops: Regular 71  (24)
Occasional 97  (33)
Never 125  (43)
No. of different medications used: 1 83  (27)
                              2 115 (37)
                              3 115 (37)
†Data missing from all categories 
Table 1: Characteristics of respondents†.
Relationships between illness and medication belief subscales and 
demographic factors were explored using Spearman’s rank correla-
tion coefficients (Mann-Whitney U test for gender). Patient subgroups 
were identified by hierarchical agglomerative cluster analysis of IPQ-R 
subscale scores, using Ward’s method [32], taking as the resemblance 
coefficient, the squared Euclidean distance between illness beliefs as 
measured by the seven cognitive and emotional subscales of the IPQ-
R [33]. As IPQ-R subscales contain differing numbers of items, values 
were standardised by transformation into Z scores. The agglomeration 
schedule was examined to determine the most appropriate number of 
clusters in the data. Independent sample t-tests (95% confidence inter-
vals and equal variance assumed), were conducted to determine wheth-
er there were any significant differences between clusters in medication 
beliefs, age, duration of illness and age of SAR onset. Cluster differences 
in gender and experience of symptoms was investigated using Chi2 tests. 
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Emotional representations were positively associated with all medica-
tion beliefs, indicating that those with stronger medication concerns 
and beliefs in the need for medication were more likely to report being 
upset or depressed by SAR.
Identification of two sub-groups of hayfever patients 
Cluster analysis of illness representations identified two subgroups 
of patients (Figure 1). Broadly speaking, 58% had ‘positive’ beliefs and 
42% had ‘negative’ beliefs. These two groups were similar in terms of 
age (t=-0.61; df=311; p>0.05), age of onset (t=-0.03; df=295; p>0.05), 
gender (χ2=0.49; p>0.05) and duration of illness (t=-0.72; df=295; 
p>0.05). However, those with negative beliefs were more likely to expe-
rience hayfever symptoms ≥ 4 days/week during the season (χ2=20.93; 
p<0.001) and to perceive their symptoms as more severe (χ2=41.70; 
p<0.001). 
Those with negative beliefs were more likely to perceive their illness 
as having greater emotional impact, greater consequences for their lives 
and as lasting longer. This group also reported a poorer understand-
ing of their illness than those holding positive beliefs (Table 5). Consis-
tently, those holding more negative beliefs attributed more symptoms 
to their hayfever, perceived they had less personal control over their 
Mean (SD) Median Min-max 
score
Cronbach’s α
IPQ-R:
Illness identity (n=237) 6.73
(3.37)
6.00 1-14 N/A
Timeline (n=314)  21.36 
(4.16)
22.00 10-30 0.80
Timeline cyclical (n=315) 12.78
(3.18)
13.00 4-20 0.70
Consequences  (n=314)   15.77
(4.42)
15.00 6-29 0.78
Personal control (n=314)   18.88
(2.95)
19.00 10-26 0.74
Treatment control (n=314)   14.64
(1.92)
15.00 9-20 0.77
Illness coherence (n=314)   17.85
(4.50)
19.00 5-25 0.91
Emotional representations 
(n=314)
  11.57
(3.94)
11.00 5-25 0.85
BMQ-Specific (n reflects number reporting use of medication)
Necessity
Oral antihistamines
(n=254)
  14.85
(4.23)
15.00 5-25 0.83
 Nasal spray (n=189)   14.30
(4.25)
14.00 5-25 0.86
 Eye drops (n=143)   13.17
(3.83)
12.00 5-22 0.82
Concerns
Oral antihistamines
(n=258)
  12.00
(3.44)
12.00 5-21 0.71
Nasal spray (n=191)   12.25
(3.39)
12.00 5-21 0.76
 Eye drops (n=143)   10.76
(3.36)
10.00 5-20 0.84
Table 2: Means (SD), medians, ranges and Cronbach’s Alpha values for illness 
perceptions (IPQ-R) and medication beliefs (BMQ).
Cause N % of sample endorsing item 
(agreeing/ strongly agreeing)
Pollen 293 93
Pollution in the environment 232 73
Hereditary - ‘it runs in my family’ 136 43
Altered immunity 102 32
Chance or bad luck 60 19
Stress or worry† 51 16
Diet or eating habits 47 15
Smoking 43 14
My own behaviour† 43 14
My emotional state e.g. feeling 
down, lonely, anxious, empty†
30 9
A germ or virus 29 9
Overwork 22 7
Alcohol 19 6
Ageing 16 5
My mental attitude e.g. thinking 
about life negatively†
10 3
Poor medical care in my past 9 3
Family problems or worries 
caused my illness†
8 3
My personality† 5 2
Accident or injury 5 2
†Emotional casual attributions [38] 
Table 3: Causal attributions of hay fever.
Beliefs about 
hay fever 
(IPQ-R)
Beliefs about hay fever medication (BMQ)
Oral antihistamines Nasal spray Eye drops
Necessity Concerns Necessity Concerns Necessity Concerns
Illness identity .255*** .135 .124 .143 .114 .041
Timeline 
(acute/chronic)
.305*** .154* .090 .146* .087 .097
Timeline 
cyclical
-.083 .177** -.013 .580 .036 .179*
Consequences .458*** .437*** .127 .274*** .297*** .430***
Personal 
control
.098 -.099 .074 .012 .143 .111
Treatment 
control
.059 .026 .083 -.085 .005 .002
Illness 
coherence
-.133* -.424*** -.039 -.199* -.043 -.397***
Emotional rep-
resentations
.301*** .435*** .160* .313*** .206* .390***
†Spearman’s correlation coefficients
*p ≤ 0.05 **p ≤ 0.005 ***p ≤ 0.001 all others non significant
Table 4: Correlation coefficients† between patient beliefs about hay fever medi-
cines and perceptions about their hay fever.
emotional 
respresen-
tations
coherence treatment 
control 
personal 
control 
conse-
quences 
timeline 
cyclical
timeline 
acute 
IPQ-R Subscale
22.50
20.00
17.50
15.00
12.50
10.00
M
ea
n 
sc
or
e
Positive belief 
cluster
Negative belief 
cluster
Belief clusters
Figure 1: Clusters of negative and positive beliefs based on IPQ-R dimen-
sions.
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illness and were less likely to believe that treatment could control their 
hayfever (Table 5). 
Patients with more negative beliefs about their SAR had stronger 
belief in the necessity of taking antihistamine tablets to improve their 
health, but there was no difference for nasal sprays or eye drops (Table 
5). However, patients with more negative beliefs reported greater con-
cerns about all three types of medication (Table 5).
Discussion   
This is the first study to use the SRM framework to explore the 
beliefs of patients with hayfever about their illness and its treatment 
[18,19]. The analysis revealed clear patterns of beliefs, linked to symp-
tom reporting and have implications for patient care. 
The strongest correlations were found between illness cognitions 
and medication beliefs. Patients reporting good understanding of their 
illness were less likely to have concerns regarding medication. Those 
who reported strong concerns about their medication and also held 
strong beliefs that medication was necessary for their health were more 
likely to experience emotional consequences, such as being upset or de-
pressed because of SAR. 
These findings have important implications for patient manage-
ment. As most SAR is managed in the community, appropriate self-
management is vital to optimising symptom control, and reducing dis-
ease impact. Patients’ understanding of their SAR could be improved 
by educational strategies, including wider use by community physicians 
and pharmacists of existing leaflets informing patients about the causes, 
symptoms and likely impact of SAR and the range of available medica-
tions. Those who had experienced SAR for longer reported stronger 
personal control beliefs and better understanding of SAR. This may 
reflect an adaptive approach to self-management as patients get used 
to having SAR. If during the consultation, the clinician identifies some-
one with negative beliefs they should encourage the patient to consider 
alternative perspectives that may encourage adaptive problem focused 
coping strategies. Even those with more positive illness cognitions did 
not strongly believe that their treatment would be effective. There are 
several possible explanations beyond the simple conclusion that treat-
ment is not very effective. Incomplete medication adherence could lead 
to poor symptom control, if patients believe that medication will not 
help their particular symptoms. Strong personal control beliefs associ-
ated with low beliefs in the necessity of medicines and high medication 
concerns may mean that patients use behavioural management options 
rather than drug therapy. These beliefs could be explored by the clini-
cian and alternative pharmaceutical options discussed. 
In general, patients did not strongly believe that their medication 
was necessary to their health. Patients’ beliefs about medication are not 
necessarily rational from a medical perspective [20], and they may be 
reluctant to disclose these beliefs to health professionals. Discussion of 
information provided in leaflets could help elicit the patient’s own be-
liefs, concerns and expectations [34]. Having explored these and having 
considered them in relation to treatment alternatives, the practitioner 
and patient could agree an appropriate treatment plan. Through shared 
ownership of the decision the patient is more likely to take the medica-
tion as recommended.
For example White et al. found that 64% of hayfever patients who 
were prescribed regular nasal steroids and antihistamines, did not take 
their medication as recommended [2]. The SRM asserts that beliefs 
affect the coping strategies that people choose [18,19], and this has 
been shown to affect adherence to medication [16]. In the SRM, non-
adherence results from incongruence within the person’s illness model. 
Previous studies have demonstrated that stronger concerns about the 
potential adverse effects of medication [16,25] and more negative time-
line and cure/control beliefs [26] are related to reduced adherence levels 
in asthma. Interventions could be designed to address concerns about 
medications and to strengthen beliefs about personal control alongside 
treatment control. 
Many patients considered their SAR was caused by pollen or pol-
lution in the environment, or a hereditary condition. This is similar to 
causal beliefs reported by members of an allergy network [29]. How-
ever, a minority attributed their illness to psychological factors such as 
stress, worry, or their emotional state. Beliefs about cause also influence 
health behaviours such as following management advice and have been 
targets for intervention. Interventions aimed at changing the causal be-
liefs of patients (e.g. patients whose perceptions of the cause of their 
myocardial infarction were unrelated to epidemiological evidence) 
have successfully changed patient outcomes [27]. Little work has been 
conducted in other, less serious conditions.
Examining patterns of beliefs may be better for identifying ‘at risk’ 
groups for intervention than targeting individual beliefs [33]. Cluster 
analyses have been applied to many patient groups, including those 
with chronic pain [35] and hypertension [36]. In the present study, 
cluster analysis revealed that people with more negative belief patterns 
were more likely to perceive that their SAR would be permanent, and 
perceived more severe consequences. This subgroup had less under-
standing of SAR and reported stronger emotional representations, as 
compared to patients with more positive beliefs. Patients with more 
Variables Positive beliefs 
cluster (n=182†)
mean (SD)
Negative beliefs 
cluster (n=132†)
mean (SD)
t Significance
(p)
IPQ-R†
Illness identity 6.14 (3.37) 
(n=135)
 7.56 (3.20) 
(n=101)
 3.27  0.001
Timeline‡  19.74 (4.00) 23.59 (3.31)  9.35 <0.001
Personal control  19.89 (2.70) 17.49 (2.71) -7.78 <0.001
Treatment control  14.85 (1.83) 14.34 (1.99) -2.34 0.02
Illness coherence  19.21 (4.11) 15.97 (4.35) -6.72 <0.001
Emotional represen-
tations‡
  9.45 (2.58) 14.48 (3.61)  13.68 <0.001
Consequences  13.30 (3.04) 19.17 (3.70)  15.43 <0.001
Timeline -cyclical  12.60 (2.99) 13.01 (3.43)  1.11 0.27
BMQ-Specific†
Necessity
    Antihistamines 14.06 (4.11)
(n=151)
16.02 (4.16)
(n=103)
 3.72 <0.001
    Nasal spray‡ 13.92 (3.90)
(n=98)
14.70 (4.59)
(n=91)
 1.26     0.21
    Eye drops 12.73 (4.06)
(n=78)
13.71 (3.49)
(n=65)
 1.53     0.13
Concerns
    Antihistamines 10.88 (3.03)
(n=154)
13.66 (3.35)
(n=104)
 6.92 <0.001
    Nasal spray 11.37 (3.16)
(n=102)
13.26 (3.39)
(n=89)
 3.98 <0.001
    Eye drops 9.84 (3.21)
(n=82)
11.98 (3.19)
(n=61)
 3.96 <0.001
†n as described unless otherwise indicated in the table 
‡equal variances not assumed 
Table 5: Independent samples t-test results across self-report measures for cluster 
groups.
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negative beliefs about SAR were also more likely to believe in taking 
antihistamines. The lack of relationships between beliefs and use of na-
sal sprays or eye drops may reflect the smaller numbers using these, 
or perhaps the more targeted nature of symptom relief as compared to 
antihistamine tablets. Negative illness perceptions have been linked to 
higher levels of psychological distress and less adaptive coping strat-
egies in allergy sufferers [29]: perhaps those reporting more negative 
beliefs may be at increased risk of these outcomes. Future studies could 
clarify how patterns of beliefs link to anxiety and depression, coping 
style and adherence. Interventions could focus on promoting more 
positive beliefs and teaching new coping strategies (pharmacotherapy 
and behavioural approaches).
The present study has some limitations. The cross-sectional design 
means we cannot determine whether medication beliefs cause beliefs 
about the illness or vice versa. Similarly, as SAR symptoms vary accord-
ing to time of year, beliefs captured at one time point may not remain 
stable all year round. A repeated measures design would better capture 
the cyclical nature of SAR and indicate the optimum timing for inter-
vention. The sample only included patients who have consulted a gen-
eral practitioner and ignores those who only self-medicate with over 
the counter remedies. It remains unknown whether beliefs or symptom 
severity differ between these two groups.
Despite these limitations, the study findings are relevant to clini-
cal practice. If clinicians gain a better understanding of their patients’ 
views about their illness and treatment, this creates a firmer founda-
tion for clinician-patient partnership [37]. Our findings demonstrate 
that the SRM illness perceptions approach offers a useful framework for 
eliciting patients’ underlying cognitive models of SAR and may help fa-
cilitate discussion about self management strategies with those holding 
negative beliefs, with the aim of arriving at appropriate and mutually 
agreed treatment plans. 
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